Last reviewed · How we verify
Centre Oscar Lambret — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
7 Phase 2
7 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Blood collection | Blood collection | marketed | ||||
| TEGAFUR URACIL - FOLINIC ACID | TEGAFUR URACIL - FOLINIC ACID | phase 3 | Antimetabolite | Thymidylate synthase | Oncology |
Therapeutic area mix
- Other · 4
- Oncology · 3
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- GERCOR - Multidisciplinary Oncology Cooperative Group · 2 shared drug classes
- Hoffmann-La Roche · 2 shared drug classes
- Asan Medical Center · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Australasian Gastro-Intestinal Trials Group · 1 shared drug class
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
- Barts & The London NHS Trust · 1 shared drug class
- Associazione Volontari Pazienti Oncologici · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Centre Oscar Lambret:
- Centre Oscar Lambret pipeline updates — RSS
- Centre Oscar Lambret pipeline updates — Atom
- Centre Oscar Lambret pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Centre Oscar Lambret — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centre-oscar-lambret. Accessed 2026-05-16.